About

Fatima Cody Stanford is an Associate Professor in the Department of Internal Medicine and Pediatrics at Harvard Medical School. She is an Obesity Medicine Physician Scientist practicing and teaching at Massachusetts General Hospital (MGH). Dr. Stanford is recognized as one of the first fellowship-trained obesity medicine physicians in the world. Her educational background includes a BS and MPH from Emory University, where she was a MLK Scholar; an MD from the Medical College of Georgia School of Medicine as a Stoney Scholar; an MPA from Harvard Kennedy School of Government as a Zuckerman Fellow; and an executive MBA from the Quantic School of Business. She completed her internal medicine and pediatrics residency at the University of South Carolina, followed by her Obesity Medicine & Nutrition Fellowship at MGH/HMS. Dr. Stanford has also served as a health communications fellow at the CDC and as a behavioral sciences intern at the American Cancer Society. Her research and clinical focus are centered on obesity, weight management, and related metabolic and nutritional health issues. She has received numerous awards for her leadership, community service, and contributions to medicine, including the AMA Leadership Award, the Joseph E. Johnson Leadership Award from the American College of Physicians, and the HMS Amos Diversity Award.

Research topics

• Sociology
• Political Science
• Medicine
• Environmental health
• Internal medicine
• Family medicine
• Gender studies
• Nursing
• Information Retrieval
• Law
• Demography
• Medical education
• Geography
• Regional science
• Psychology
• Business
• Psychiatry
• Virology
• Pediatrics

Selected publications

• ChatGPT for obesity management: a review of evidence, potential challenges, and clinical implications

  The Lancet Digital Health · 2026-04-01

  articleOpen accessSenior author

  The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity management. ChatGPT, one of the fastest-growing artificial intelligence (AI) tools, is gaining attention for its potential to offer interactive support in managing complex conditions such as obesity. In this Review, we used a thematic synthesis approach to examine ChatGPT's effect on obesity management. We analysed studies from PubMed, Web of Science, and supplementary sources published between Dec 1, 2022, and Oct 31, 2025, focusing on the applications, effectiveness, and limitations of ChatGPT in obesity management, including its roles in patient support, education, behavioural guidance, and clinical decision making. 37 studies (29 original and eight review-based studies) were included in this Review. Among the original studies, ChatGPT showed high accuracy in nine (75%) of 12 obesity-related lifestyle and nutrition studies and five (50%) of ten bariatric surgery studies compared with expert or guideline standards. Compared with other AI tools (eg, DeepSeek, Copilot, Gemini, Bing, Bard, and DALL·E 3), ChatGPT showed higher overall accuracy; however, evidence from comparisons with specialised applications or algorithms remains scarce. Quality assessment ratings were mostly moderate, and only ten (27%) of the total 37 studies were rated as high confidence. Overall, ChatGPT offers opportunities in eight areas of obesity management: lifestyle support, user engagement, clinical empowerment, medication guidance, virtual assessment, surgical guidance, predictive modelling, and research assistance. However, its implementation is limited by challenges in six key domains: accuracy and reliability, algorithmic bias, cultural sensitivity, transparency and accountability, excessive dependence, and ethical and legal concerns. Addressing these challenges is essential before ChatGPT can be considered for clinical deployment to safeguard patient safety and optimise its effectiveness in obesity management.

  PublisherDOI

• Nutritional priorities to support <scp>GLP</scp>‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

  Obesity · 2025-05-30 · 74 citations

  articleOpen access

  BACKGROUND: Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness. OBJECTIVES: We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician. METHODS: An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions. RESULTS: GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity. CONCLUSIONS: Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP-1 treatment of obesity, making clinicians more effective in advancing their patients' health.

  PublisherOA PDFDOI

• Personalized Lifestyle Interventions for Prevention and Treatment of Obesity-Related Cancers: A Call to Action

  Cancers · 2025-04-08 · 3 citations

  articleOpen accessSenior author

  The increasing global burden of cancer necessitates innovative approaches to prevention and treatment. Lifestyle factors such as diet, physical activity, and smoking significantly contribute to cancer. At the same time, current guidelines are based on a one-size-fits-all approach, which limits their effectiveness across diverse populations. Obesity is a well-documented risk factor for cancer, directly affecting 13 types of cancer. The complex interplay of genetic, metabolic, hormonal, and environmental factors in obesity's etiology highlights the need for more tailored approaches to obesity-related cancers. This perspective article advocates for a shift toward an integrative, personalized approach that considers a variety of intrinsic and extrinsic factors associated with the etiology of obesity-related cancers. Lifestyle-based cancer prevention strategies should be tailored to an individual's biological profile, demographic background, behaviors, and environmental exposures. Following a diagnosis, a comprehensive treatment approach should consider how these genetic, physiological, lifestyle, and environmental factors interact in the onset and progression of the disease while also taking cancer type and stage into account. This approach paves the way for more precise and effective strategies in tackling cancer. Fulfilling collaboration across research, healthcare, and policy sectors is essential to achieve these goals.

  PublisherOA PDFDOI

• Corrigendum to “The need for increasing pediatric obesity advocacy.” [Volume 80 (2024) 1–2]

  Complementary Therapies in Medicine · 2025-10-17

  erratumOpen accessSenior author
  PublisherDOI

• Compassionate care in obesity management: reclaiming humanity in health care

  The Lancet Diabetes & Endocrinology · 2025-04-22 · 2 citations

  articleSenior author
  PublisherDOI

• Inflation as a gut health crisis: The SAFEGUARD framework

  Clinics and Research in Hepatology and Gastroenterology · 2025-08-20

  articleSenior authorCorresponding
  PublisherDOI

• Reply to GM Tinsley et al.; DB Ibsen et al.; and EJ Dhurandhar et al.

  American Journal of Clinical Nutrition · 2025-09-09

  letterOpen access1st authorCorresponding
  PublisherOA PDFDOI

• Overcoming Weight Bias in Health Care Systems

  The American Journal of Managed Care · 2025-09-15 · 1 citations

  articleSenior author

  This commentary calls for health care systems to deliver equitable care for people living with obesity by addressing weight bias and updating standards in obesity care.

  PublisherDOI

• Estimating the association and timing of occurrence between obesity and related comorbidity outcomes in a real‐world setting: A cohort study in the United States

  Clinical Obesity · 2025-06-04

  articleOpen accessSenior author

  Summary To understand the prevalence, incidence and sequence of obesity‐related comorbidities (ORCs) among people with obesity compared with those with a normal body mass index (BMI). People with obesity (BMI ≥30 kg/m 2 ) and normal BMI (BMI 18.5 to &lt;25 kg/m 2 ) were matched 1:1 using a large United States claims‐linked electronic health record database. The index date was the date of the first qualifying BMI. Prevalence was assessed at baseline (12 months pre‐index date); incidence and sequence of new ORCs were assessed during follow‐up. Each cohort included 57 978 people. At least 1 ORC was present at baseline in 61.1% and 49.6% of the obesity and normal BMI cohorts, respectively. During follow‐up (median 61 months) event rates per 1000 person‐years of new ORCs were higher in the obesity cohort than the normal BMI cohort (572 vs. 378, respectively). In both cohorts, musculoskeletal pain was the most frequent new ORC, followed by dyslipidemia and hypertension. Median times to the first, second and third new ORC were shorter in the obesity cohort compared with the normal BMI cohort by 0.67, 0.81 and 0.66 years, respectively. People with obesity had a higher prevalence and incidence, and accelerated onset of ORCs compared with those with normal BMI.

  PublisherOA PDFDOI

• Increasing Diversity in the Nutrition, Obesity, and Diabetes Biomedical Workforce: The BRIDGES Consortium

  UNC Libraries · 2025-04-05

  articleOpen access
  PublisherDOI

Recent grants

• Creating Opportunities for Unparalleled Researchers to Achieve Growth and Excellence (COURAGE)

  NIH · $3.3M · 2022–2027

• Accelerating Research Advancement for Early Career Investigators in Academia

  NIH · $480k · 2023–2028

Frequent coauthors

• Vibha Singhal

  Harvard University

  117 shared

• Madhusmita Misra

  Massachusetts General Hospital

  104 shared

• Miriam A. Bredella

  Harvard University

  100 shared

• Karen J. Campoverde Reyes

  University of California, San Francisco

  73 shared

• Félix Gilbert

  63 shared

• William Barclay

  Imperial College London

  55 shared

• High Road

  Royal College of Music

  52 shared

• Lucy Ogbu-Nwobodo

  University of California, San Francisco

  51 shared

Education

• M.D.

  Harvard Medical School

• B.S.

  University of California, Berkeley

Awards & honors

• Gold Congressional Award
• American Medical Association (AMA) Foundation Leadership Awa…
• AMA Paul Ambrose Award for national leadership among residen…
• AMA Inspirational Physician Award (2015)
• Joseph E. Johnson Leadership Award from the American College…